Upstream Bio Reports Positive Phase 2 VALIANT Trial Results for Verekitug in Severe Asthma, Plans Phase 3

summarizeSummary

Upstream Bio reported positive Phase 2 results for verekitug in severe asthma, meeting its primary endpoint with significant reductions in exacerbations and demonstrating a favorable safety profile, paving the way for Phase 3 development.

check_boxKey Events

• Phase 2 VALIANT Trial Met Primary Endpoint

  Verekitug achieved statistically significant and clinically meaningful reductions in the annualized asthma exacerbation rate (AAER) in severe asthma patients, with reductions of 56% (p<0.0003) for 100 mg q12w dosing and 39% (p<0.02) for 400 mg q24w dosing compared to placebo.

• Clinically Meaningful Secondary Endpoint Improvements

  The trial also showed clinically meaningful improvements in lung function (FEV1) and suppressed exhaled nitric oxide (FeNO) with both effective dose regimens.

• Favorable Safety Profile

  Verekitug was generally well tolerated across all active doses, demonstrating a safety profile consistent with previous studies.

• High Patient Rollover to Long-Term Extension Study

  Over 90% of eligible patients from the VALIANT trial have rolled over to the Phase 2 VALOUR long-term extension study, indicating strong patient and physician confidence.

auto_awesomeAnalysis

Upstream Bio announced highly positive top-line results from its Phase 2 VALIANT trial for verekitug in severe asthma. The drug met its primary endpoint with statistically significant and clinically meaningful reductions in asthma exacerbation rates across two dosing regimens, alongside improvements in lung function and exhaled nitric oxide. The favorable safety profile and high patient rollover rate into the long-term extension study further de-risk the program. These strong results provide a clear path for advancing verekitug into Phase 3 trials, significantly bolstering the company's pipeline and market potential in a substantial therapeutic area.